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I want to begin by thanking the Association and yourpresident for this tremendous honor. I received Dr
Loop’s invitation in December 1996. Since then I have
looked forward to this meeting with considerable antic-
ipation and not a little trepidation.
There is a particular significance to my being here
today. It was 21 years ago exactly—1977 in Toronto—
that I first attended a meeting of The American
Association for Thoracic Surgery (AATS) and gave a
presentation. That was my first visit to North America
with my wife and our son and daughter (then aged 5 and
2). Immediately after the AATS meeting we drove to
Cleveland, Ohio, for what was to be the first of many
visits with Dr Loop and his colleagues at The Cleveland
Clinic. That happy association has spanned 21 years.
Where do I begin? The logical place to start is at the
beginning, with the title of this lecture: “A Practical
Affair.” These are the words of John Heysham Gibbon,
Jr, the man who developed and first used a heart-lung
machine successfully in clinical cardiac surgery in
1953. His words were recorded 5 years earlier: “Some
day the heart-lung machine will become a practical
affair.” That successful operation on May 6, 1953,
exactly 45 years ago tomorrow, opened the doors to a
new era in the treatment of heart disease. It is salutary
to note in Ada Romaine-Davis’s book on John Gibbon
and his heart-lung machine that preoperative cardiolog-
ic diagnosis for the 18-year-old patient was less than
precise. The operation note section on preoperative
diagnosis offered a generous, if inexact, range of possi-
bilities. In fact, the patient had a large atrial septal
defect, necessitating 26 minutes of full cardiopul-
monary bypass (CPB) support for successful closure.
John Gibbon’s “some day” of 1948 became a reality
in 1953. But what of the phrase, “a practical affair?” Is
that what CPB (the technology of the heart-lung
machine and the practice of perfusion) has become?
There is something intriguing about the phrase, “a prac-
tical affair.” The term “affair” conjures up many things
in the mind, but permanence is not one of them. In rela-
tionships, it suggests that, however bright, however
exciting at the start, it will not last.
In this lecture, I wish to develop the argument that, as
cardiac surgeons, we need to reconsider our involve-
ment in the technology and the practice of CPB. Rather
than viewing CPB as a historical development, one in
which problems have been solved, challenges met, and
safe techniques established—yesterday’s news—I wish
to suggest that we need to reengage our minds and
efforts. In short, for cardiac surgeons, CPB cannot
afford to be just “a practical affair.” It has to be “a com-
mitted relationship.” If some of you are thinking that
there is no case to answer, let me develop my hypothe-
sis and set out the case to be answered.
Cardiac surgeons have failed to maintain their
involvement with and understanding of CPB. This lack
of involvement (both practical and intellectual) has led
to unfamiliarity, progressive lack of understanding, and
nonparticipation. For many cardiac surgeons, perfusion
has become almost a “no-go area.”
Compare the pioneers of the 1950s and 1960s with
the surgeons of today. Could your trainees put together
a CPB circuit? Could they run a perfusion? In our train-
ing programs there is a paucity of teaching in CPB prac-
tice and technology. We are creating a new generation
of cardiac surgeons unfamiliar with CPB.
I believe that we have abrogated our responsibility in
relation to CPB. Since the pioneer phase, we have
focused almost exclusively on the developments of sur-
gical technique. You may be saying that our responsi-
bility does not extend to the extracorporeal circuit. That
is the perfusionists’ area. They are the experts. Indeed
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they are. However, in 1980 a position statement on car-
diovascular perfusion was issued by the councils of The
American Association for Thoracic Surgery (AATS)
and The Society of Thoracic Surgeons (STS). The final
paragraph, published in The Journal of Thoracic and
Cardiovascular Surgery in February 1980, contained
this statement concerning responsibility:
The American Association for Thoracic Surgery and
the Society of Thoracic Surgeons firmly believe that the
ultimate responsibility for the conduct of a surgical pro-
cedure requiring cardiopulmonary bypass resides with
the physician/surgeon-in-charge. We also recognize the
responsibility of other involved physicians and allied
health personnel in conducting such a procedure. How-
ever, it must be understood that the surgeon in charge is
morally, legally, and ethically responsible for the care of
the patient.*
I was amused to note that, 6 months later, the Journal
published a small but intriguing correction. It said, in
relation to the statement, “the last sentence should read
as follows: ‘However, it must be understood that the
surgeon in charge is morally and ethically responsible
for the care of the patient.’”1 Morals and ethics are one
thing. Clearly, legal implications are something else!
The concept of the surgeon’s ultimate responsibility
for the conduct of a surgical procedure requiring CPB
was restated by the AATS/STS in 1983 and again in
1986.
Acceptance of responsibility is an important part in
establishing any committed relationship, but it is cer-
tainly not the only part, or even the most important. In
any successful relationship, the driving forces must be
both positive and stimulating. Looking back in compla-
cency is not enough, however successful the past has
apparently been.
In relation to the cardiac surgeon/CPB relationship, I
want to consider with you two important topics: (1) the
fact that there is still a lot to learn and (2) the need to
practice the team approach.
Accounts of the early days of cardiac surgery make
for exciting reading—tremendous effort, high drama,
elation, and despair. In Gibbon’s own story, not only
was there the high point of May 6, 1953, there were
three other days, one in February 1952 and two in July
1953, when the patients (baby girls aged 15 months, 51⁄2
years, and 51⁄2 years, respectively) did not survive, lead-
ing to a self-imposed moratorium on cardiac surgery
with CPB. In the United Kingdom, the Hammersmith
team (Cleland, Bentall, and Dennis Melrose, who
developed the UK heart-lung machine) would place a
rose on the CPB console for every case, and every child
having a successful operation was allowed to choose a
rabbit from the animal house to take home as a pet.
In those early days, the challenges to be faced daily
were monumental. Nowadays, it seems so different.
Safety and reliability are never in doubt. Technology is
sophisticated, yet relatively inexpensive, and mortality
is a mere fraction of that in the 1950s. Yet there is still a
lot to learn. If we think that CPB is now “as good as it
gets,” we delude ourselves. If we think all the big ques-
tions have been answered, we are wrong. Although CPB
is less traumatic now than in the early days, it remains
far from being physiologic. It has its own unique patho-
physiology that continues to contribute to the morbidity
and even mortality of cardiac surgery procedures. I
believe the challenges for research and development are
just as great as they were 50 years ago.
Let me illustrate by giving some examples from three
important areas of CPB pathophysiology: (1) adequacy
of blood flow delivery to organs and tissues; (2) gas
exchange and acid-base balance; and (3) blood cell
activation, inflammation, and hemostasis.
Just to make the point that there is still a lot to learn,
I am going to focus on only one organ potentially
affected by these processes during CPB—the brain. We
do not have time to consider other vital organs affected
by this pathophysiology, such as the lungs, kidneys,
gastrointestinal tract, liver, and the heart itself.
Cardiac surgeons are interested in the brain. Certainly,
the fact that the brain is damaged to some extent during
cardiac surgery with CPB has been known since the ear-
liest days. In 1954, the year that Gibbon published his
article, another article reported the occurrence of brain
injury in patients undergoing surgery with CPB. As a
profession, we have had 45 years to solve this problem.
How much progress have we made?
Blood flow delivery
The first point to consider is blood flow delivery.
What do we know about cerebral blood flow (CBF)
during CPB? What are the normal patterns of CBF?
What happens to CBF during cardiac surgery? Is any
fall in CBF during CPB sufficient to cause brain dam-
age? Are there subgroups of patients at high risk for
brain injury during CPB?
We know that CBF is an autoregulated system (Fig 1)
in which flow is maintained across a wide range of per-
fusion pressures (approximate range of mean systemic
blood pressures, 50-150 mm Hg). Above and below
these limits, CBF becomes pressure passive. The
autoregulation of CBF is a nice example of the homeo-
*From Statement on Extracorporeal Technology. J Thorac Cardiovasc
Surg 1980;79:316.
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static plateau concept of Claude Bernard: the “milieu
interior,” “the constancy of the internal environment is
the necessary condition for the free life.” This autoreg-
ulated system is reassuring, but what happens to CBF
during cardiac surgery?
Investigators have reported that CBF falls to a vari-
able extent (range 20+ mL · 100 g–1 · min–1) during
CPB and then returns to near normal levels in the post-
CPB period. We should note that CBF levels may be
influenced by various factors, notably temperature and
arterial PCO2 levels. We should also be aware that
autoregulation of CBF may itself be lost under certain
circumstances, notably with deep hypothermia (15°C-
20°C) and with pH-stat acid-base management.
However, the key question is surely this: If CBF can
fall during CPB to 20 to 25 mL · 100 g–1 · min–1, is this
fall sufficient to cause brain cell damage? This question
is answered by Astrup’s concept of brain ischemic
thresholds. He and his colleagues2 reported in 1977
that CBF had to fall below 10 mL · l00 g–1 · min–1 for
ischemic cell death to occur, and this threshold was
established at normothermia; hypothermia afforded
increased protection (Fig 2).
These data challenge the often-stated belief that the
brain is very sensitive to reduced global perfusion. In
fact, the brain appears relatively resistant to reduced
CBF and to reduced systemic blood pressure.
However, I am not advocating complacency. There
are identifiable groups of patients at increased risk of
brain injury during cardiac surgery. These include
elderly patients, hypertensive patients, patients with
flow-limiting cerebrovascular stenoses, and patients
with a previous cerebrovascular accident.
Alterations to the CBF-autoregulated plateau may be
the explanation for the increased risk in some of these
groups. Certainly, the CBF lower limit of autoregula-
tion is higher in patients with chronic hypertension.
The whole curve shifts to the right. In elderly patients,
it is not unreasonable to suggest that, with increased
age, the width of the autoregulatory plateau may be
progressively reduced, but I am not aware of any
research on this topic.
Gas exchange and acid-base protocols during CPB 
I shall now consider how gas exchange and acid-base
management during CPB might affect the brain. For
Fig 1. Autoregulation of cerebral blood flow for normotensive and hypertensive patients.
Fig 2. Cerebral ischemic thresholds. CBF, Cerebral blood
flow.
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many years, the only gas really worth bothering about
during cardiac surgery was oxygen. Although the pio-
neers used the term artificial lung to describe that com-
ponent of the CPB circuit, the term oxygenator soon
replaced it. This change was more than mere semantics,
for the lung does more than oxygenate: (1) gas
exchange is not equivalent to oxygenation and (2) gas
exchange involves the introduction of oxygen plus the
removal of carbon dioxide.
Preoccupation with oxygenation may lead to a num-
ber of unfortunate consequences:
• The mistaken belief that, if the arterial return blood
from the CPB circuit is bright red, then all is well with
the world. (The brighter the better!)
• Failure to recognize that gaseous microbubbles and
gaseous microembolism are generated in direct propor-
tion to the arterial PO2 level
• Failure to be aware of the importance of control
of arterial PCO2 in relation to CBF and cerebral
microembolism
Looking first at cerebral microembolism, the elegant
studies carried out by Blauth and associates3 used fluo-
rescein retinal angiography to image the retinal circula-
tion during cardiac surgery. The eye develops embry-
ologically as an outgrowth from the brain, taking its
blood supply directly from the cerebral circulation.
Retinal angiography, therefore, provides a unique win-
dow on the events occurring in the cerebral circulation.
In their early studies (Fig 3, A and B), Blauth and
Arnold showed diffuse occlusions in retinal arterioles
during CPB, with consequent loss of perfusion to areas
of the retina. They used computerized image analysis
to quantify the ischemic areas produced.
In subsequent studies, they compared bubble oxy-
genators and membrane oxygenators and found a sub-
stantial reduction in retinal defects in the membrane
oxygenator group. The incidence of defects was
reduced from 100% in the bubble oxygenator group to
under 50% in the membrane group. The great advan-
tage of membrane oxygenation relates to the ability to
control oxygen and carbon dioxide independently, thus
avoiding the over-oxygenation produced by high-effi-
ciency bubble oxygenators, particularly in the rewarm-
ing phase of CPB. However, this 50% improvement,
welcome though it was, has not to my knowledge pro-
gressed any further.
Fig 3. Retinal fluorescein angiograms obtained from a patient undergoing coronary bypass graft surgery. A,
Angiogram obtained 5 minutes before onset of CPB. B, Angiogram obtained after 60 minutes of CPB. Note trun-
cation of vessels and loss of blood vessel filling in angiogram B in the segment between the 10-o’clock and 1-
o’clock positions on the macula (central dark object).
A B
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Turning now to acid-base management during
hypothermic CPB, we come face to face with the
alpha-stat/pH-stat question. I have come to the conclu-
sion that this topic is not so much controversial as con-
fusing. In the basic science part of the United
Kingdom’s cardiothoracic surgical specialty fellowship
examination, I often ask the candidates, “Which stat
protocol do you use in your unit?” Invariably, the
answer comes quickly and confidently: “Alpha/pH.”
Right then, I say, “Tell me the difference between these
strategies.” This is usually where it all comes unstuck,
particularly if the candidate tries to explain what the
alpha of alpha-stat stands for. It is the perfect excuse to
hand out BAIK badges—Boy Am I K(c)onfused.
The essential difference in these two approaches
relates to what happens to carbon dioxide. As core tem-
perature is reduced, carbon dioxide going into solution
increases, PCO2 falls, and pH rises. With alpha-stat
management, no intervention is undertaken. With pH
stat management, sufficient additional carbon dioxide
is introduced via the oxygenator to maintain the pH at
physiologic normothermic levels.
With the pH-stat strategy, therefore, total carbon
dioxide content is increased. “So what?” you say. As
far as the brain is concerned, pH-stat management has
a number of consequences:
• Autoregulation of CBF is impaired or even lost
completely
• CBF is relatively increased by the increase in PCO2
compared with alpha-stat levels
• The ratio of CBF to cerebral metabolic needs is
altered
The significance of the changes in flow/metabolism
ratios needs further discussion. CBF/metabolism ratio
expresses the adequacy of CBF in supplying the neces-
sary amounts of energy substrate to meet cerebral
metabolism, conventionally expressed as the cerebral
metabolic rate for oxygen (CMRO2). At normothermia,
CBF is around 40 mL · 100 g–1 · min–1 and CMRO2 is
around 2.5 to 3 mL · 100 g–1 · min–1. The ratio of flow
to metabolism is therefore around 15:1.
See what happens to CBF and CMRO2 with progres-
sive cooling: CBF reduces linearly with reducing tem-
perature, whereas CMRO2 reduces exponentially. At
28°C, therefore, the flow/metabolism ratios are signifi-
cantly altered, and the choice of alpha-stat or pH-stat
management also affects the ratios. At 28°C with
alpha-stat management the ratio increases to 30:1, but
with pH-stat management the ratio increases to 60:1.
One might think superficially that this must be good,
with a mighty excess of CBF over the metabolic needs
of the brain. However, this degree of “luxury perfu-
sion” is at best unnecessary and at worst deleterious,
increasing the embolic load delivered to the brain (both
gaseous and particulate).
Historically, in the 1960s and 1970s, the standard
acid-base protocol in CPB was pH-stat. The physiolog-
ic basis for alpha-stat management began to emerge in
the mid to late 1980s. However, to reiterate the point
that we still have a lot to learn, the argument has moved
again in the mid 1990s, with studies from Richard Jonas
and colleagues that suggest that the pH-stat strategy
may be associated with improved cerebral outcomes, at
least in pediatric practice. It is all very confusing.
Blood cell activation, inflammation, and hemostasis
If our understanding of the issues of blood flow
delivery and gas exchange/acid-base balance has pro-
Fig 4. Contact activation flow diagram.
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gressed somewhat from Gibbon’s day, albeit with more
unanswered questions now than when it all began, in
the area of blood cell activation we have scarcely
scratched the surface. CPB imposes unphysiologic con-
tact between the patient’s blood and the surfaces of the
extracorporeal circuit. The term contact activation has
been used to describe the complex series of cascades
involving the coagulation, fibrinolytic, kallikrein, and
complement systems (Fig 4), leading ultimately to acti-
vation of white blood cells and platelets with the gen-
eration of a systemic inflammatory response syndrome
(SIRS).4
The inflammatory response is one of the most fun-
damental protective responses we possess, but it func-
tions as a local response, focusing the body’s defenses
at the point of injury. The problem in cardiac surgery
is that the response becomes systemic, potentially dis-
tributed throughout the body, affecting all vital organs
and tissues.
The new disciplines of molecular biology and genet-
ic science have allowed us to begin to characterize
those events that establish the inflammatory response,
particularly the interactions between leukocytes and
vascular endothelium.5
The sequence of events causing inactive leukocytes
to move from free flow in the circulating blood and
become activated and localized in tissues, producing
inflammation, is thought to be as follows (Fig 5):
• Rolling of leukocytes along the endothelium is
mediated by adhesion molecules called selectins
• The rolling movement progresses to firm attachment
of the leukocyte to endothelium, mediated by integrins
• Finally, the adherent, activated leukocyte moves
through the endothelial layer into the extravascular tis-
sue, a process known as transmigration, also mediated
by integrins
This is a concise, simplified view of inflammation.
But is this what happens in patients undergoing cardiac
surgery? These are the questions we need to ask: Is
CPB a stimulus to the development of SIRS? Is it an
inevitable consequence of CPB? Is the pattern of SIRS
in cardiac surgery the same as or different from the
response in other disease states?
We honestly do not know the answers to these vital
questions as yet. Research in this area is progressing
rapidly. It is interesting, however, to mention some
work my own department published in the mid 1980s,
when we were trying to characterize the effects of CPB
on leukocyte trapping in the lung6 (Fig 6, A, B, and C).
• Before CPB, the leukocyte lies free in the pul-
monary capillary
• Thirty minutes after CPB, the leukocyte has become
attached to the pulmonary capillary endothelium (firm
adhesion)
• Two hours after CPB, the leukocyte is growing foot-
like processes (pseudopodia) and is moving through
the endothelium into the extravascular space (transmi-
gration)
Do these effects relate to the brain as well as the
lung? We think they may. In 1993 we carried out a pilot
study of immediate postoperative brain imaging using
magnetic resonance imaging (MRI) in six patients
undergoing coronary surgery.7 When I say immediate,
I mean immediate. The patients were transferred from
Fig 5. Leukocyte/endothelial interaction steps in the process of inflammation.
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the operating theater to the MRI suite with the images
being obtained within 60 minutes of the end of the
operation. Each patient had optimal 1990s CPB with
moderate hypothermia, alpha-stat acid-base manage-
ment, pulsatile perfusion, arterial filtration, and mem-
brane oxygenators. None of the preoperative MRIs
showed abnormalities, and in all six patients the imme-
diate postoperative image revealed acute brain swelling
(Fig 7, A and B). The swelling was not present 24 hours
after the operation. These observations represent an
acute perioperative situation. All six patients had a
rapid, uneventful postoperative recovery, specifically
with no central nervous system complications.
These findings challenged our complacency. Even
with the optimal cerebral protective measures known to
date, our current practice leads to this structural change
in the brain.
We have just completed a major follow-up study to
investigate further this phenomenon and assess whether
therapy designed to modify the SIRS might prevent, or
at least reduce, this acute brain swelling. This prospec-
tive, randomized, placebo-controlled, double-blind
study in patients undergoing coronary artery bypass
grafting involved the following:
• Brain MRI: less than 24 hours before the operation,
immediately after the operation, and 12 months after
the operation
• Neuropsychologic assessment: before the operation
and 8 days, 8 weeks, and 12 months after the operation
• SIRS markers: leukocyte profiles, adhesion mole-
cules (selectins, integrins), and inflammatory cytokines
The therapeutic agent in the study is aprotinin, the
protease inhibitor drug with potentially widespread
inhibition of several of the inflammatory cascades. The
results of the study will not be known for some time,
until the drug/placebo codes are broken. However, we
do know that we have (1) patients in whom MRIs in the
immediate postoperative period show no abnormalities
and (2) patients with marked inhibition of the patterns
of leukocyte activation and inflammation.
I have spent a good deal of time on the topic, “We’ve
still got a lot to learn.” I now want to deal more briefly
with my second positive point regarding committed
relationships: the need to practice the team approach.
The idea is that the partners in the relationship bring
complementary attributes.
You need only walk into a cardiac surgery operating
room to understand that a cardiac operation involves a
large team of people. I used the term “operating room”
advisedly. In the United Kingdom, we use the term
“operating theater.” I have often thought that the pref-
erence for “theater” reinforces the perception that sur-
geons in general, and cardiac surgeons in particular, are
true prima donnas.
You may have begun to think, “I detect some incon-
sistency creeping in. Earlier you were saying, ‘The sur-
geon carries ultimate responsibility.’ Now you are say-
ing, ‘It is a team effort.’ Surely you cannot have it both
ways.”
I do believe that the surgeon should continue to carry
Fig 6. Leukocyte/endothelial cell interaction in a pulmonary
capillary. Scanning electron microscope images of lung biopsy
specimens obtained. A, Before CPB; B, 30 minutes after
CPB; C, 120 minutes after CPB.
A
B
C
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ultimate responsibility, but as for any captain (of a
team, of a ship, or of an aircraft), that responsibility is
accepted in the context of a collaborative effort. This
has to be true for the cardiac surgical team in general
and, to be specific to my subject, for the relationship
between cardiac surgeons and the technology and prac-
tice of CPB.
I want to consider two other partners in this relation-
ship: the perfusionist and industry. I hope to convince
you all that the right involvement of surgeons, in col-
laboration with perfusionists and industry, will promote
progress, with added value for all concerned.
Development of perfusionists—professional and
educational
In the early days of cardiac surgery, the role of the
perfusionist was, to say the least, somewhat arbitrary.
On-the-job training was the order of the day, with little
or no formal training or structured syllabus. This was
hardly surprising, given that these were pioneering days.
Formal perfusionist training programs began to appear
in the 1970s, initially driven by the manpower require-
ments in the larger units. In 1973, in the United States,
programs existed only at The Cleveland Clinic,
Pittsburgh Shadyside, and the Texas Heart Institute.
Board certification of perfusionists was introduced in
1975, with the establishment of the American Board of
Cardiovascular Perfusion. Establishment of the Board
was not without incident, and tensions between the per-
fusionists and cardiac surgeons were evident in the late
1970s and early 1980s, although they have been resolved.
The support of the AATS and STS for perfusionists’
formal training and continued professional develop-
ment was made clear in the 1980s when the
Coordinating Committee on Perfusion Affairs was
established under the wise leadership of Gerald Rainer.
On the other side of the Atlantic, the process was
similar. Various national perfusionist societies were
established in the 1960s and 1970s. Some moved rapidly
to formal training and certification (eg, the Dutch
Society, NeSECC). In the United Kingdom, the level of
perfusionist education was further advanced in 1983
when the United Kingdom School of Perfusion
Sciences was established—fully supported by the
A B
Fig 7. Magnetic resonance images of the brain of a patient undergoing coronary bypass surgery. A, Image ob-
tained 24 hours before the operation. B, Image obtained 60 minutes after the coronary bypass operation. 
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United Kingdom Societies of Cardiothoracic Surgeons
and Cardiothoracic Anaesthetists—and the Society of
Perfusionists. The School of Perfusion Sciences estab-
lished a two-year postgraduate diploma in perfusion
science and now offers an additional master of science
degree in perfusion science. In 1991, the European
Board of Cardiovascular Perfusion was established,
again with the full support of the European Association
for Cardiothoracic Surgery (EACTS), the European
Society of Cardiovascular Surgery, and the European
Association of Cardiothoracic Anaesthesiologists. The
current chairman of the European Board of
Cardiovascular Perfusion is a cardiac surgeon, Ludwig
von Segesser, from Lausanne, Switzerland.
These steps in professional development of perfu-
sionists have been paralleled by steady progress in aca-
demic activities. The two principal North American
societies, the American Society for Extra-Corporeal
Technology (AMSECT) and the American Academy
for Cardiovascular Perfusion, have published their
respective journals/proceedings for several years. In
1986, the first issue of Perfusion, the international spe-
cialty journal for CPB, was published. The journal is
now in its thirteenth year of publication, fully cited in the
Cumulated Index Medicus, and with particularly close
links with international perfusion societies (American
Academy for Cardiovascular Perfusion, European
Board, and Australasian Society of Perfusion).
I have been particularly gratified, over the 13 years of
publishing Perfusion, to see the steady increase in the
quantity, and especially the scientific quality, of manu-
scripts received from the perfusion community.
Experience with the peer review process has been uni-
formly beneficial.
I believe that the emergence of perfusion as a profes-
sion allied to medicine is a wholly positive develop-
ment. The AATS/STS statement on perfusionist affairs
in 1982 set the pattern: “Encourages and supports the
efforts of the organized bodies of extracorporeal tech-
nologists to improve the quality of education for perfu-
sionists and promote research and continuing education
to insure high standards of practice and safety of
patients undergoing extracorporeal circulation.”8
I believe that, to a considerable extent, these laudable
objectives have been achieved. The team effort in car-
diac surgery has benefited enormously from the profes-
sional development of perfusionists. They now repre-
sent a real technologic and research resource, and we
cardiac surgeons should, must, engage with them. But
the initiative must come from the cardiac surgeons,
because the fundamental issue of responsibility has not
changed. It remains, in my view, as it was restated by
Richard Clark and George Magovern9 in a 1982 edito-
rial in The Journal of Thoracic and Cardiovascular
Surgery: “The further success of the profession of car-
diovascular perfusion depends clearly upon continued
recognition by cardiac surgeons as well as perfusionists
that the conduct of cardiac surgery and cardiopul-
monary bypass is properly the ultimate responsibility
of the cardiac surgeon.”
The team approach as it applies to industry
I do not know what your approach is to representa-
tives of manufacturing or pharmaceutical companies. I
suspect, however, that many cardiac surgeons are
increasingly reluctant to meet and discuss issues/new
products in the area of perfusion. If my original
hypothesis is correct, why should we get into situations
in which our relative unfamiliarity with and ignorance
of perfusion matters may become only too obvious? If
that assessment is unfair, I apologize, but my percep-
tion is that industry may have more access to and dis-
cussions with the perfusionist than with the cardiac sur-
geon. If cardiac surgeon/industry communication is not
occurring, then both sides lose. Cardiac surgeons lose
out on new thinking and new possibilities in technolo-
gy or pharmacology, and industry loses out on the clin-
ician’s real grasp of clinical reality. The one who picks
up the final bill is the patient.
The clinical reality issue is very important. Over the
years, a number of giant leaps in perfusion technology
have been hailed by industry and variably accepted into
perfusion practice. I believe some are spurious in con-
cept and impotent in practice. Here are some of my per-
sonal bêtes noires:
• “Physiologic” or, as we prefer to say, “physiological”
• “State of the art” technology. What does that mean,
other than that it was introduced today as opposed to
yesterday?
• Low priming volume components, when we are not
able to prevent the vascular permeability changes of the
SIRS
• Heparin-coated circuits and biocompatibility. I
accept that surface modification of CPB circuits is
conceptually attractive, but heparin is not the optimal
substance
These are only a few examples, but to substantiate
my prejudices, here are direct quotes from 10 arbitrar-
ily selected, consecutive ads in a recent cardiac surgery
journal:
• “State of the art”—mentioned three times
• “Physiologic”—mentioned three times
• “Low priming volume”—mentioned twice
• “Biocompatibility”—mentioned twice
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I am certainly not trying to be offensive. Rather, I feel
very strongly that great opportunities are being missed:
opportunities for a two-way education process between
cardiac surgeons and industrial research and develop-
ment; opportunities and responsibilities of cardiac sur-
geons to reengage in selection of perfusion equipment
and technology; and combined involvement of clinicians
and industry in the education process, particularly in the
introduction of new concepts and new technologies.
Summary
There we have it. I have rehearsed my original argu-
ment that, for us as cardiac surgeons, the technology
and practice of CPB cannot just be a practical affair. It
has to be a committed relationship driven by our cur-
rent ignorance (there is still a lot to learn) and charac-
terized by the team approach (while the surgeon retains
ultimate responsibility). Some specific challenges are
obvious:
• CPB in pediatric practice. Listen to these words:
We believe that the quality of CPB practiced upon chil-
dren must improve and continue to improve.
We hope that we will be able to stimulate some among
you to take up arms in the fight against the morbidity it
[CPB] can produce.
Many of the technical battles in [adult] cardiac surgery
have been won, but, for CPB in children, we the combat-
ants have barely entered the field.10
The preceding statements were not written in the
early days of CPB, but as recently as 1994.10
• Brain protection, when, with the best of current
knowledge and practice, this is the picture immediately
after apparently straightforward, successful coronary
surgery
• The new technologies and practice of less invasive
CPB and the extended role of CPB
I began with John Gibbon, prophetic in 1948, reality
in 1953. But I discovered that Dr Samuel Johnson was
well ahead of his time. In the 1700s he knew about
SIRS. “SIRS,” he said, “I have found you an argument,
I am not obliged to find you an understanding.”11 In
this area of cardiac surgical practice, he may not have
felt obliged to find an understanding, but we must. That
is the challenge—to reengage in CPB and see it as inte-
gral to our profession and practice as cardiac surgeons,
not a practical affair, but a committed relationship.
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